8-K: Edwards Lifesciences Q2 2026 Earnings Beat Expectations

Edwards Lifesciences reported strong second quarter 2026 results, exceeding sales growth expectations and raising full-year guidance for key product lines.

Summary

• Edwards Lifesciences announced its financial results for the second quarter ended June 30, 2026.
• Total sales reached $1.74 billion, a 13.6% increase year-over-year (12.5% on a constant currency basis).
• Transcatheter Aortic Valve Replacement (TAVR) sales grew 11.3% to $1.26 billion (10.5% constant currency).
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales surged 47.3% to $195.9 million (44.8% constant currency).
• Surgical sales increased by 6.5% to $284 million (5.0% constant currency).
• Reported EPS was $0.42, with adjusted EPS at $0.78.
• The company raised its full-year 2026 constant currency sales growth guidance to 10%-11% from 9%-11%.
• Full-year TAVR constant currency sales growth guidance was increased to 8%-9% from 7%-9%.
• Full-year TMTT sales guidance was raised to $760-$780 million from $740-$780 million.
• Full-year adjusted EPS guidance remains $2.95 to $3.05.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong sales growth, raised guidance, and positive clinical data, indicating robust performance and future potential despite some minor headwinds.

Positives

• Strong Q2 sales growth of 13.6% ($1.74 billion), exceeding expectations.
• Significant TAVR sales growth of 11.3% ($1.26 billion), driven by clinical momentum and SAPIEN platform durability.
• Exceptional TMTT sales growth of 47.3% ($195.9 million), fueled by PASCAL and EVOQUE systems.
• Raised full-year 2026 sales growth guidance for total company (10%-11%) and TAVR (8%-9%).
• Increased full-year TMTT sales guidance to $760-$780 million.
• Reaffirmed adjusted EPS guidance of $2.95-$3.05, indicating confidence in profitability.
• Positive clinical data presented for SAPIEN platform at New York Valves, reinforcing performance and durability.
• Expected Q4 approvals for PASCAL tricuspid indication in the U.S. and next-generation PASCAL in U.S. and Europe.

Negatives

• Gross profit margin expected at the lower end of the full-year guidance (78%-79%) due to foreign exchange headwinds.
• Effective tax rate for 2026 is expected at the high end of the previous range (16%-19%) due to potential Pillar Two legislation and California tax law changes impacting R&D credits.
• A $188.2 million valuation allowance was recorded against certain deferred tax assets due to California legislation impacting R&D credits.

Risks

• Potential impact of the Centers for Medicare & Medicaid Services (CMS) reconsideration of the National Coverage Determination (NCD) for TAVR, with a final decision expected in September.
• Risks associated with the failure to successfully innovate and market products.
• Unsuccessful clinical trials or procedures.
• Manufacturing, logistics, or quality issues.
• Competition in the medical device market.
• Dependence on key physicians, research institutions, and hospital systems.
• Global, economic, political, and social conditions.
• Inability to obtain governmental reimbursement or reductions in reimbursement levels.

Future Outlook

Edwards Lifesciences has increased its full-year 2026 guidance for total company constant currency sales growth to 10%-11% (from 9%-11%), TAVR constant currency sales growth to 8%-9% (from 7%-9%), and TMTT sales to $760-$780 million (from $740-$780 million). The company is reaffirming its adjusted EPS guidance of $2.95-$3.05. They anticipate the effective tax rate to be at the high end of the 16%-19% range.

Management Comments

• "We delivered stronger-than-expected second quarter sales growth of 12.5%. As Edwards continues to invest in new structural heart therapies and expand adoption globally, our results increasingly reflect the strength of our comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as meaningful contributions from each of the regions."
• "Today, our company profile has evolved to include multiple strategic platforms across multiple regions that will support durable growth, which gives us confidence in our target of approximately 10% total company sales growth, on average, over the longer term."
• "Our strategic focus coupled with our commitment to early innovation enables us to deliver meaningful impact for patients worldwide."

Industry Context

StockSavvy.ai notes that Edwards Lifesciences' strong Q2 performance, particularly in TAVR and TMTT, aligns with broader industry trends of increasing adoption of minimally invasive structural heart procedures. The company's raised guidance reflects confidence in its product pipeline and market penetration against a backdrop of evolving clinical guidelines and competitive dynamics.

Comparison to Industry Standards

• Edwards' TAVR sales growth of 10.5% (constant currency) in Q2 2026 is robust, especially considering the mature nature of some markets. Competitors like Medtronic (with its Evolut platform) and Abbott (with its Portico system) are also vying for market share, but Edwards' long-term durability data for its SAPIEN platform continues to be a key differentiator.
• The TMTT segment's 44.8% constant currency growth is exceptional, outpacing many peers in this rapidly expanding field. This growth is driven by their PASCAL and EVOQUE systems, positioning them strongly against competitors in mitral and tricuspid repair and replacement.
• The company's commitment to R&D as a percentage of sales (16.0% in Q2 2026) remains significant, reflecting an industry-wide emphasis on innovation to address unmet patient needs and maintain competitive advantage.

Legal Proceedings

• The company incurred certain litigation expenses related to intellectual property litigation, settlements, contingencies, and external legal costs.

Stakeholder Impact

• Shareholders: Positive impact due to increased sales growth guidance and reaffirmed EPS guidance, suggesting continued financial performance and potential for value appreciation.
• Patients: Continued innovation and expansion of access to life-changing structural heart therapies like TAVR, TMTT, and surgical solutions.
• Healthcare Providers: Ongoing support through clinical data, new product introductions, and expanded adoption of advanced therapies.
• Employees: Continued investment in R&D and global expansion may lead to growth opportunities within the company.

Next Steps

• Expected presentation of PROGRESS trial results at TCT later this year.
• Expected Q4 approvals of PASCAL tricuspid indication in the U.S.
• Expected Q4 approval of next-generation PASCAL with Capture Clarity in the U.S. and Europe.
• Continued measured launch of the SAPIEN M3 system in the U.S. and Europe.
• Planned measured rollout of the ECLIPTIS surgical left atrial appendage system later this year.
• Final decision memo from CMS regarding the NCD for TAVR expected in September.

Key Dates

Recommendation

The company demonstrated strong Q2 performance exceeding expectations, raised full-year guidance for key growth drivers (TAVR, TMTT), and continues to innovate with promising clinical data and upcoming product approvals. The robust growth in structural heart therapies, coupled with a solid financial outlook, presents a compelling investment case.

Keywords

TAVR, TMTT, Structural Heart, Medical Devices, Cardiovascular, Surgical Valves, Healthcare, Financial Results